Search clinical trials for: Cyclophosphamide and fludarabine

Total 272132 results

TCR2 Therapeutics
Bristol-Myers Squibb

Active, not recruiting

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Cholangiocarcinoma | Non Small Cell Lung Cancer Metastatic | Mesotheliomas Pleural | Mesothelioma Peritoneum | Mesothelioma; Pleura | Cholangiocarcinoma Recurrent | High Grade Ovarian Serous Adenocarcinoma

United States, Canada
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Ovarian Cancer

China
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML (GITMO-AMLR2)

Acute Myeloid Leukemia (AML)

Italy, Israel
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Baylor College of Medicine

Completed

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation

Kidney Cancer

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

Melanoma (Skin)

United States
Zhejiang University
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

BCMA CAR-NK For Patients With RRMM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Masonic Cancer Center, University of Minnesota
National Marrow Donor Program

Completed

Stem Cell Transplant for Hemoglobinopathy

Sickle Cell Disease | Thalassemia | Severe Congenital Neutropenia | Diamond-Blackfan Anemia | Shwachman-Diamond Syndrome

United States
French Innovative Leukemia Organisation

Completed

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

Leukemia

France
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
Allife Medical Science and Technology Co., Ltd.
Tianjin People's Hospital

Recruiting

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Memorial Sloan Kettering Cancer Center

Completed

Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
M.D. Anderson Cancer Center

Completed

CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

Leukemia | Advanced Cancers

United States
Cancer and Leukemia Group B
National Cancer Institute (NCI)

Completed

Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma

Lymphoma | Leukemia

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
M.D. Anderson Cancer Center

Withdrawn

Infusion of Allogeneic, 3rd Party CD19-specific T Cells

Lymphoma | Leukemia | Blood And Marrow Transplantation
Hoffmann-La Roche
Genentech, Inc.; Biogen

Completed

FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients

Chronic Lymphocytic Leukemia

United States, Italy, Belgium, Canada, Spain, Australia, France, Russian Federation, Netherlands, New Zealand, Denmark, Romania, Poland, Hungary, United Kingdom, Sweden, Norway
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Northwestern University
National Cancer Institute (NCI)

Withdrawn

Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery

Kidney Cancer | Testicular Germ Cell Tumor | Breast Cancer | Lung Cancer | Melanoma (Skin)
Cancer Research UK

Unknown

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

Lymphoma

United Kingdom
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Withdrawn

Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies (UCALL)

Lymphoid Hematological Malignancies | Umbilical Cord Blood Transplant
Han weidong

Recruiting

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | Decitabine-primed Tandem CD19/CD20 CAR T Cells

China
Cancer Trials Ireland

Completed

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Leukemia

Ireland
National Cancer Institute (NCI)

Completed

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

Breast Cancer

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL

Allogeneic Hematopoietic Stem Cell Transplantation | Acute B Lymphoblastic Leukemia

China
Fujian Medical University

Unknown

A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma

China
Institute of Hematology & Blood Diseases Hospital
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia

AML, Adult

China
Hoffmann-La Roche
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia (CLL-8)

Leukemia

France, Australia, Belgium, Italy, Germany, Israel, New Zealand, Czech Republic, Spain, Austria, Denmark
National Cancer Institute (NCI)

Completed

Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

MDS | Immunodeficiency | GATA2

United States
Cancer Research UK

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia

United Kingdom
German CLL Study Group
Genzyme, a Sanofi Company; University of Cologne

Completed

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

T-cell-prolymphocytic Leukemia

Germany
Vastra Gotaland Region

Recruiting

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML (SCRIPT-AML)

Stem Cell Transplantation | Acute Myeloid Leukemia (AML) in Remission

Belgium, Denmark, Finland, Hong Kong, Israel, Lithuania, Netherlands, Norway, Spain, Sweden
Corregene Biotechnology Co., Ltd

Recruiting

CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

Cervical Cancer | Anal Cancer | Head and Neck Cancers

China
National Heart, Lung, and Blood Institute (NHLBI)
GlaxoSmithKline; University of Virginia

Completed

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Small Lymphocytic Lymphoma | CLL (Chronic Lymphocytic Leukemia)

United States
Patrick C. Johnson, MD
AstraZeneca

Recruiting

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma (DLBCL) | Grade 3b Follicular Lymphoma | Refractory Aggressive B-cell Lymphomas | Aggressive B-cell NHL | De Novo or Transformed Indolent B-cell Lymphoma | DLBCL, Nos Genetic Subtypes | T Cell/Histiocyte-rich Large B-cell Lymphoma and other conditions

United States
M.D. Anderson Cancer Center
Intrexon Corporation

Terminated

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Acute Myeloid Leukemia | Hematopoietic/Lymphoid Cancer

United States
Massachusetts General Hospital

Recruiting

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Renal Failure

United States
Memorial Sloan Kettering Cancer Center

Completed

A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

Leukemia | Cancer | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome

United States
Zhejiang University
Hangzhou Qihan Biotech Co.,Ltd.

Recruiting

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

AML, Adult

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Minimal Residual Disease

China
BGI, China
Sun Yat-sen University

Completed

Treatment of Advanced Solid Tumor With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)

Solid Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
German CLL Study Group

Completed

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Prolymphocytic Leukemia

Germany, Austria
Chinese PLA General Hospital

Recruiting

TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Hackensack Meridian Health
Celgene Corporation

Completed

Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide (FCR)

Chronic Lymphocytic Leukemia (CLL)

United States

Search clinical trials for: Cyclophosphamide and fludarabine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations